ClinicalTrials.gg
SuspendedNCT06465537Updated Aug 20, 2026

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

An interventional study of BD113vVLP in Primary Open Angle Glaucoma, sponsored by Shanghai BDgene Co., Ltd.. Suspended at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Shanghai BDgene Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
Per the requirement of China regulation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Glaucoma, Open-Angle with a site in China — 7 open to participants now, 11 under way, 1 of them phase 3. Glaucoma, Open-Angle · China.

Planned enrollment
29th of 30
9 · median 120
Started
2024
with 4 others
No phase
14 of 38
2 open now
Registered
31st of 38
by date

Among the 38 studies in Glaucoma, Open-Angle with a site in China, this one is the 29th largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2024, is one of 14 with no phase, and was the 31st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 38 studies in Glaucoma, Open-Angle with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Glaucoma, Open-Angle with a site in China, or all of them as a file.
02

Study summary

This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma (POAG) with elevated intraocular pressure and MYOC gene mutation. The main objectives to evaluate the safety and tolerability BD113vLVP) in POAG patients with intraocular hypertension and MYOC mutation, and secondary objectives is to explore the preliminary efficacy and the metabolism characteristics of BD113vLVP in participants.

Read the detailed description

This is an open, single-dose, two-arm, non-randomised clinical study. A total of 6 to 9 POAG patients with high intraocular pressure were enrolled and divided into two test groups. Test Group 1 recruits 3 POAG patients, who have elevated IOP and positive or negative MYOC mutation and target interventing eye is no vision. Test Group 2 will recruit 3 to 6 POAG patients with MYOC mutations and visual acuity. In order to better verify the lowering IOP effectiveness of BD113vVLP, another 2 or 3 participants will be recruied in Group 2 on-demand. Each participant will receive single dosing BD113vVLP (4µg p24) by intracameral injection in the interventing eye, then conduct the evaluations of the safety and efficacy according to visit schedule in 1 year follow-up。

03

Conditions studied

  • Primary Open Angle Glaucoma

Keywords

  • primary open angle glaucoma
  • POAG
  • elevated intraocular pressure
  • MYOC gene mutation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ICF;
  2. Aged 18 to 65 years old;
  3. Primary open Angle glaucoma (POAG) with elevated intraocular pressure (IOP) was diagnosed with ≥1 year medical history record ;
  4. Good function level of organs;
  5. Good compliance and willing to comply with the visit schedule, laboratory tests and other specified test etc. per protocol;
  6. Agreeing to accept a long-term safety follow-up after 1 year of study.

Special Inclusion Criteria for Group 1:

  • Target intervenning eye is no visual acuity;
  • The intraocular pressure (IOP) was ≤35 mmHg and > 21 mmHg after receiving a combination therapy of 2 or more drugs lowering IOP.

Special Inclusion Criteria for Group 2:

  • MYOC gene mutation was detected in peripheral blood nucleated cells ;
  • The intraocular pressure (IOP) was ≤30 mmHg and > 21 mmHg after receiving a combination therapy of 2 or more drugs lowering IOP;
  • Both eyes have a Shaffer Angle mirror rating greater than 3.

Exclusion criteria

Exclusion Criteria:

  1. Secondary glaucoma;
  2. Any active or recurrent intraocular infection or inflammation, including but not limited to uveitis;
  3. The target intervenning eye has severe xerophthalmia or active corneal disease;
  4. Any condition no accepting the measure of IOP;
  5. Any positive of type 1/2 (HIV-1/HIV-2) antibody, treponema pallidum (TP) specific antibody, human T-lymphotropic virus type 1 or 2 (HTLV-1/HTLV-2) antibody, or vesicular stomatitis virus G (VSV-G) antibody;
  6. Any of virus (HBV) HbsAg or HBV-DNA, virus (HCV) HCAb, or epstein-barr virus (EBV), or cytomegalovirus (CMV) nucleic acid test is positive;
  7. Severe active bacterial, viral, fungal, malaria or parasitic systemic infection;
  8. Any past or present , myeloproliferative or immunodeficient disease;
  9. History of major organ diseases or abnormalities in laboratory tests, including:

    1. Liver cirrhosis, liver fibrosis or active hepatitis, and/or abnormal liver function tests (serum total (TBIL) ≥1.5 x (ULN); (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN; Alkaline phosphatase ≥2.5 × ULN);
    2. Cardiovascular and cerebrovascular diseases, including uncontrolled hypertension, myocardial infarction, myocarditis, arrhythmia, stroke, etc.;
    3. Kidney disease, or creatinine ≥ 1.5ULN and \< 30% normal level (using the Cockcroft-Gault equation);
    4. Endocrine disorders, such as insulin-dependent diabetes mellitus, hyperthyroidism or hypothyroidism;
    5. Severe pulmonary hypertension, , interstitial pneumonia;
  10. Any severe psychiatric disorders;
  11. Participating in another clinical study of a drug or device, or administrated the drug within 42 days prior to the screening visit;
  12. Pregnant or lactating women;
  13. Refusing to accept any measures;
  14. Allergic to clinical investigational drugs or their ;
  15. Other conditions assessed by the investigator as unsuitable for participation in this study.

Special Exclusion Criteria for Group 2:

  • Retinal diseases: complicated with unexplained quadrant blindness, neovascularization age-related macular degeneration, retinal branch vein obstruction, central retinal vein obstruction, cystoid macular edema, macular hiatal hole and central serous retinopathy;
  • A history of anterior chamber angle stenosis, congenital glaucoma, or angle closure, clinically significant anterior peripheral adhesion, or extensive cicatricial adhesion caused by surgery/laser therapy in the anterior chamber angle;
  • The central corneal thickness is less than 480 μm or more than 620 μm.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Group 1: POAG without vision for interventional eye

    Interventional eye of participants with POAG has no vision, with mutated or unmutated MYOC gene. Single dose of BD113vVLP will be administrated intracamerally for target interventional eye.

    Genetic: BD113vVLP

  • Experimental
    Group 2: POAG with vision for interventional eye

    Interventional eye of participants with POAG has vision acuity, and MYOC gene mutation test is positive. Single dose of BD113vVLP will be administrated intracamerally for target interventional eye.

    Genetic: BD113vVLP

Interventions

  • GeneticBD113vVLP

    CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.

    Also known as: BD113 virus-like particle, CRISPR/Cas9 mRNA instantaneous gene editing technology

06

What researchers measure

Primary outcomes

  1. Ocular adverse events (AEs)

    The charactaristics of ocular adverse events include endophthalmitis, hypopyon, hyphaema and corneal injection site reaction etc. will be evaluated at Week 1, Week 2, Week 3, Week 4, Month 6 and Month 12 after BD113vVLP administration.

    Time frame: 12 months

  2. Number and percentage of participants whose IOP decrease ≤21 mmHg

    at Month 1, Month 2, Month 3, Month 6 and Month 12 after BD113vVLP administration

    Time frame: 12 months

Secondary outcomes

  1. Systemic adverse events (AEs): The type, number and incidence of AEs and serious adverse events (SAEs)

    Systemic adverse events (AEs): The type, number and incidence of AEs and serious adverse events (SAEs) will be analysized within 12 months after BD113vVLP administration.

    Time frame: 12 months

  2. Number and percentage of participants whose IOP decrease by ≥ 20% from baseline

    at Month 1, Month 2, Month 3, Month 6 and Month 12 after BD113vVLP administration

    Time frame: 12 months

  3. Any ocular maligancies related to BD113vVLP

    after BD113vVLP administration

    Time frame: 12 months

  4. Changes in BCVA from baseline

    at Month 3, Month 6 and Month 12 after BD113 vVLP administration, not applicable to group 1.

    Time frame: 12 months

  5. Changes in visual fields from baseline

    at Month 3, Month 6 and Month 12 after BD113 vVLP administration, not applicable to group 1.

    Time frame: 12 months

  6. Changes in RNFL from baseline

    at Month 3, Month 6 and Month 12 after BD113 vVLP administration, not applicable to group 1.

    Time frame: 12 months

  7. P24 and Cas9 proteins concentration in aqueous humor

    at hour 0 and Month 1 after BD113vVLP administration

    Time frame: 1 months

  8. P24 and Cas9 proteins concentration in blood

    at hour 0 and Day 7 after BD113vVLP administration

    Time frame: 7 days

  9. Blood antibodies of anti-p24 protein and anti-Cas9 proteins

    at Month 6 and Month 12 after BD113vVLP administration

    Time frame: 12 months

07

Study locations

1 site
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Apr 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 20, 2024
StartActual
Jun 10, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06465537
Lead sponsor
Shanghai BDgene Co., Ltd.
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Jun 10, 2024
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Yufei Teng, M.D.
study director · Beijing Tongren Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion